RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway-Reference-Cited by-同舟云学术

RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-ERK pathway

Published:2023-05-04 Issue:24 Volume:42 Page:2017-2030
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Feng Zhigang,Ke Shanjia,Wang Chaoqun,Lu Shounan,Xu Yanan^ORCID,Yu Hongjun,Li Zihao,Yin Bing,Li Xinglong,Hua Yongliang,Qian Baolin,Bai Miaoyu,Fu Yao,Zhang Yingmei,Wu Yaohua^ORCID,Ma Yong^ORCID

Funder

Natural Science Foundation of Heilongjiang Province

Heilongjiang Provincial Postdoctoral Science Foundation

China Postdoctoral Science Foundation

National Natural Science Foundation of China

Outstanding Youth Training Fund from Academician Yu Weihan of Harbin Medical University (2014),Scientific Foundation of the First Affiliated Hospital of Harbin Medical University

Scientific Foundation of the First Affiliated Hospital of Harbin Medical University

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

https://www.nature.com/articles/s41388-023-02710-w.pdf

Reference39 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.

3. Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62.

4. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238–55.